投资者可于 2025 年 12 月 1 日（星期一）至 12 月 5 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 autobio@autobio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 郑州安图生物工程股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 8 日下午 15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 证券代码：603658 证券简称：安图生物 公告编号：2025-079 郑州安图生物工程股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

Group 1 - Baidu's Biotech Company, Bai'ao Saitou, is set to launch its IPO on the Sci-Tech Innovation Board, aiming to raise 1.185 billion yuan for early drug development services, antibody drug research, and working capital [1] - Changchun High-tech's subsidiary received approval for its clinical trial application for GenSci142 capsules, marking the first approval under the new 30-day review channel for innovative drugs [2] - Antu Bio announced it received 18 medical device registration certificates, enhancing its product offerings and competitiveness in the market [3] Group 2 - Yidu Tech reported a revenue of 358 million yuan for the six months ending September 30, 2025, reflecting an 8.7% year-on-year growth, with a narrowed loss of 15.76 million yuan [4] - Baiyunshan's subsidiary, Guanghua Pharmaceutical, will receive a total compensation of approximately 449 million yuan for land and fixed assets included in a land reserve program, which aligns with the company's long-term development goals [5]

Core Viewpoint - Antu Biology has received a medical device registration certificate from the Henan Provincial Drug Administration for products including the "Interleukin-4 Test Kit" [1] Company Summary - Antu Biology's revenue composition for the year 2024 is projected to be 98.17% from in vitro diagnostics and 1.83% from other businesses [1] - As of the report, Antu Biology has a market capitalization of 21 billion yuan [1]

Core Viewpoint - The report from Guotai Junan Securities indicates that Antu Biology's domestic business is under short-term pressure, while the overseas market is experiencing rapid growth. The company is expected to stabilize its domestic business and achieve significant growth in international markets due to ongoing product registration and market expansion efforts [1]. Group 1: Business Performance - Antu Biology's domestic business is currently facing short-term challenges, but there is potential for recovery as industry policies are gradually implemented and the ecosystem becomes more rational [1]. - The company is projected to see a steady advancement in the installation of chemical luminescence instruments and assembly lines, which will support the recovery of its domestic business [1]. Group 2: Market Opportunities - The overseas market is expected to grow rapidly as the company progresses with product registrations and market development [1]. - The recent acquisition of medical device registration certificates for 14 new products, including various antigen test kits and nucleic acid test kits, enhances the company's product line and lays a foundation for future growth [1]. Group 3: Valuation and Rating - Based on comparable company valuations, Antu Biology is assigned a target price of 44.94 yuan with a 2026 PE of 21X, maintaining a "Buy" rating [1].

证券代码：603658 证券简称：安图生物 公告编号：2025-078 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及全 资子公司安图实验仪器（郑州）有限公司（以下简称"安图仪器"）于近日收到 河南省药品监督管理局颁发的医疗器械注册证，具体如下： 根据国家药品监督管理局官网数据查询信息，截至公告日，国内外同行业部 分厂家已取得上述部分类似产品的医疗器械注册证。详情请登录国家药品监督管 理局（https://www.nmpa.gov.cn）查阅。 三、对公司的影响 上述医疗器械注册证的取得进一步丰富了公司产品菜单，不断满足市场需 求，是对公司现有检测产品的有效补充，可以逐步提高公司产品的整体竞争力， 短期内对公司的经营业绩影响较小。 四、风险提示 上述产品上市后实际销售情况取决于未来市场的推广效果，目前尚无法预测 上述产品对公司未来营业收入的影响，敬请投资者注意投资风险。 特此公告。 | ...

Core Viewpoint - Antu Biology (603658.SH) has received medical device registration certificates from the Henan Provincial Drug Administration for multiple testing kits, indicating a significant regulatory approval milestone for the company [1][2]. Group 1: Company Developments - Antu Biology and its wholly-owned subsidiary, Antu Experimental Instruments (Zhengzhou) Co., Ltd., have recently obtained medical device registration certificates [1]. - The registered products include various interleukin testing kits and allergy-specific IgE antibody testing kits, showcasing the company's focus on immunological diagnostics [2]. Group 2: Product Details - The registered products include: - Interleukin 4, 5, 8, 10 testing kits (magnetic microparticle chemiluminescence method) - Specific IgE antibody testing kits for egg white, house dust, sesame, and cockroach allergens (magnetic microparticle chemiluminescence method) - Other testing kits for methoxytyramine, cyclosporine, and various antibodies (magnetic microparticle chemiluminescence method and liquid chromatography-tandem mass spectrometry) [2].

Core Viewpoint - Antu Biology (603658.SH) has received multiple medical device registration certificates from the Henan Provincial Drug Administration, enhancing its product offerings and competitiveness in the market [1] Group 1 - The acquisition of medical device registration certificates enriches the company's product menu [1] - The new certifications effectively supplement the company's existing testing products [1] - The short-term impact on the company's operating performance is expected to be minimal [1]

Core Viewpoint - Antu Bio and its wholly-owned subsidiary Antu Instruments have received 18 medical device registration certificates from the Henan Provincial Drug Administration, enhancing the company's product portfolio [1] Group 1: Company Developments - Antu Bio obtained 17 registration certificates, while Antu Instruments received 1 certificate, which includes products such as interleukin-4 testing kits and prenatal screening risk calculation software [1] - The registration certificates are valid for 5 years, indicating a long-term potential for product sales [1] Group 2: Market Context - Some domestic and international manufacturers have already obtained similar product registration certificates, suggesting a competitive landscape [1] - The short-term impact on the company's performance is expected to be minimal, and future sales performance of the new products remains uncertain [1]

Investment Rating - The report maintains a rating of "Accumulate" for the company [6][13]. Core Views - The company's domestic business is under short-term pressure, while the overseas market is experiencing rapid growth. The product line continues to expand, justifying the "Accumulate" rating [2][13]. Financial Summary - Total revenue for 2023 is projected at 4,444 million, with a slight increase to 4,471 million in 2024, followed by a decrease to 4,121 million in 2025, and then a recovery to 4,619 million in 2026 and 5,180 million in 2027 [4]. - Net profit attributable to the parent company is expected to be 1,217 million in 2023, decreasing to 1,194 million in 2024, and further down to 1,059 million in 2025, before rising to 1,224 million in 2026 and 1,409 million in 2027 [4]. - Earnings per share (EPS) is forecasted to be 2.13 in 2023, decreasing to 2.09 in 2024, and 1.85 in 2025, with a recovery to 2.14 in 2026 and 2.47 in 2027 [4][14]. Market Performance - The current stock price is 37.20, with a target price set at 44.94, indicating potential upside [6][7]. - The company has a total market capitalization of 21,257 million [7]. Business Outlook - The company is expected to see a stabilization in domestic business as industry policies are gradually implemented, and the process of import substitution accelerates [13]. - The overseas market is anticipated to grow rapidly due to ongoing product registrations and market expansion efforts [13]. - The product line has been enriched with 14 new products recently obtaining medical device registration, laying a foundation for future growth [13].

- The report discusses the "Volume Timing Signal" model, which indicates a cautious view for all indices as of November 21, 2025[24][25] - The "Number of Rising Stocks in the CSI 300 Index" sentiment indicator is used to gauge market sentiment by calculating the proportion of stocks with positive returns over a certain period[25][26] - The "Number of Rising Stocks in the CSI 300 Index" timing tracking involves smoothing the indicator over two different periods to capture its trend, with a bullish view when the short-term line is above the long-term line[27][28][29] - The "Moving Average Sentiment Indicator" uses the eight moving averages system to assess the trend state of the CSI 300 Index, assigning values based on the position of the moving average range[33][34][35] - The "Moving Average Sentiment Indicator" shows that the CSI 300 Index is currently in a non-prosperous sentiment range as of November 21, 2025[33][36][37] Model Backtest Results - Volume Timing Signal: All indices show a cautious view as of November 21, 2025[24][25] - Number of Rising Stocks in the CSI 300 Index: The indicator has recently declined, with the proportion of rising stocks slightly above 50%, indicating cooling market sentiment[25][26] - Number of Rising Stocks in the CSI 300 Index Timing Tracking: Both the fast and slow lines are declining, with the fast line below the slow line, indicating a cautious view for the near future[27][28][29] - Moving Average Sentiment Indicator: The CSI 300 Index is in a non-prosperous sentiment range as of November 21, 2025[33][36][37] Factor Construction and Evaluation - Cross-sectional volatility: The recent week saw a decline in cross-sectional volatility for CSI 300 and CSI 500 index constituents, indicating a deteriorating short-term alpha environment, while the CSI 1000 index constituents saw an increase, indicating an improving short-term alpha environment[2][38] - Time-series volatility: The recent week saw a decline in time-series volatility for CSI 300 index constituents, indicating a deteriorating alpha environment, while the CSI 500 and CSI 1000 index constituents saw an increase, indicating an improving alpha environment[2][39][40] Factor Backtest Results - Cross-sectional volatility: - CSI 300: 2.28% (recent quarter average), 83.44% (recent quarter average as a percentile of the past two years) - CSI 500: 2.44% (recent quarter average), 78.57% (recent quarter average as a percentile of the past two years) - CSI 1000: 2.60% (recent quarter average), 83.67% (recent quarter average as a percentile of the past two years)[39] - Time-series volatility: - CSI 300: 0.73% (recent quarter average), 77.23% (recent quarter average as a percentile of the past two years) - CSI 500: 0.53% (recent quarter average), 80.16% (recent quarter average as a percentile of the past two years) - CSI 1000: 0.27% (recent quarter average), 82.07% (recent quarter average as a percentile of the past two years)[42]